Sirion Therapeutics Announces Positive Phase III Results For Difluprednate

Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced positive preliminary results from its Phase III difluprednate (ST-601) program, which evaluated the steroid’s potential to rapidly resolve inflammation in the eye following ocular surgery. “We are very pleased with the data that demonstrate difluprednate’s potential as a potent, well-tolerated steroid treatment for post-operative inflammation,” said Dr. [click link for full article]

More: continued here

Filed under: Clinical Trials on October 26th, 2007